CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

Similarly, Zepbound is Mounjaro’s weight-loss counterpart ... said many of his patients report life-changing weight loss while on GLP-1 medications. “I have some veterans who have lost ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...